Overview

Pharmacokinetics and Safety of BI 695501 Administered Via Prefilled Syringe or Autoinjector

Status:
Completed
Trial end date:
2016-10-04
Target enrollment:
Participant gender:
Summary
To investigate and compare the pharmacokinetics, safety and tolerability of BI 695501 administered subcutaneously via prefilled syringe or autoinjector
Phase:
Phase 1
Details
Lead Sponsor:
Boehringer Ingelheim